Chief Executive Officer
Michael spearheads Digital Biology leadership and strategy at Cardea. Michael has an extensive background in tech business development in Bioinformatics, Next-Gen Sequencing, Genomics, and Intercellular communication. He has held leadership positions at CLC bio, BGI, EXO Incubator, Nanosens, and BlueSEQ before heading up the leadership team at Cardea Bio Inc.
Chief Scientific Officer
Kiana is a pioneer of combining CRISPR with modern electronics. She received her PhD in Biomedical Engineering at Rutgers University and continued her postdoctoral studies in bioengineering at UC Berkeley. She is a recipient of the National Institutes of Health postdoctoral training fellowship at the Buck Institute for Age Research and is a consultant for the Gates Foundation. Her efforts have been recognized within the scientific community by the Clinical OMICs 10 under 40 Award, Athena Pinnacle Award in Life Sciences, and Nature Research Awards for Inspiring Women in Science: Scientific Achievement Category’s Overall Winner. Dr. Aran is also the recipient of numerous government grants to develop the next generation of electronic biosensors.
Chief Entrepreneur
Ross is responsible for new expansions and key projects at Cardea including scaling up the chip production for Cardea and help setting up partnerships. With an MBA from San Diego State University, Ross has held positions in supply chain, operations, and finance from companies such as General Dynamics and UBC Financial Services. Ross brings precision execution and implementation to the company.
Board Member
Seth Lowry is a partner at JDP Capital Management. JDP is a private investment fund based out of New York and Amsterdam. At JDP, Seth co-chairs the investment committee for public and private technology investments. Prior to his current role, Seth was an analyst for Tech Coast Angels, which is one of the largest active angel investment syndicates in the world. Seth began his career in investment banking on Wall St. and spent a decade in working in various advisory roles for Merrill Lynch and Citigroup.
Board Member
Early in her career, Barry worked at Genaissance Pharmaceuticals after which she spent 12 years helping build Illumina, where she ultimately served as the Vice President of Applied Genomics and led pioneering teams in precision medicine, translational genomics, population genomics, and clinical screening applications, among others. Barry was a 2016 TEDx San Diego speaker, San Diego Business Journal’s Business Woman of the Year in 2017 and a Girl Scouts San Diego Cool Women recipient in 2019. Barry's current company, LunaPBC, has received numerous awards from notable institutions including the Word Economic Forum and Fast Company.
Executive Chairman
Chairman of the Innovation Council and Chairman of the Board of Directors of Cardea. Dr. Grint has served on the Boards of Illumina, AmpliPhi Biosciences, and as the CEO of several companies. Dr. Grint’s ability to see the early potential in technology served Illumina well when Next Generation Sequencing was in its infancy as it will Cardea with its Biology-gated Transistors.
Council Member
A visionary Key Opinion Leader in bringing the most advanced forms of big data and analytics to healthcare. Dr. Stupka’s work has contributed to the understanding of the human genome, transcriptome, and the development of gene-therapeutics. His understanding of data and its role in enhancing the value of new technology will help steer Cardea’s data management capabilities and add value to every Innovation Partner application.